10-hydroxystearic acid compositions
10786453 ยท 2020-09-29
Assignee
Inventors
Cpc classification
A61K8/342
HUMAN NECESSITIES
A61Q17/04
HUMAN NECESSITIES
A61K47/16
HUMAN NECESSITIES
A61K47/10
HUMAN NECESSITIES
A61K31/20
HUMAN NECESSITIES
A61K2800/30
HUMAN NECESSITIES
A61K8/604
HUMAN NECESSITIES
A61K47/08
HUMAN NECESSITIES
A61K47/14
HUMAN NECESSITIES
A61K8/39
HUMAN NECESSITIES
A61K9/0014
HUMAN NECESSITIES
A61K8/608
HUMAN NECESSITIES
A61K8/375
HUMAN NECESSITIES
International classification
A61K47/08
HUMAN NECESSITIES
A61K31/20
HUMAN NECESSITIES
A61K47/16
HUMAN NECESSITIES
A61K47/14
HUMAN NECESSITIES
A61K47/10
HUMAN NECESSITIES
A61K9/00
HUMAN NECESSITIES
A61K8/39
HUMAN NECESSITIES
Abstract
The present invention relates to topical compositions comprising 10-hydroxystearic acid or a salt thereof and at least one nonionic emulsifier. The present invention also relates to a method to retard or inhibit the re-crystallisation of 10-hydroxystearic acid or a salt thereof in a topical composition, said method comprising formulating 10-hydroxystearic acid or a salt thereof in the presence of at least one nonionic emulsifier.
Claims
1. A topical composition comprising: 0.001 to 5 wt. %, based on the total weight of the composition, of 10-hydroxystearic acid or a salt thereof, at least one nonionic emulsifier, and a co-emulsifier selected from the group consisting of nonionic solid fatty alcohols having from 12 to 22 carbon atoms and mixtures thereof, wherein the topical composition is an oil/water (O/W) emulsion comprising at least 10 wt. % of an oily phase and at least 50 wt. % of an aqueous phase, based on total weight of the composition, with the proviso that the composition is free of isobutylparabene.
2. The topical composition according to claim 1, which is also free of a cooling agent and/or an exothermic agent.
3. The topical composition according to claim 1, wherein the nonionic emulsifier is present in an amount of 0.1 to 7 wt. %, based on the total weight of the composition.
4. The topical composition according to claim 1, wherein the 10-hydroxystearic acid is (R)-10-hydroxystearic acid.
5. The topical composition according to claim 1, wherein the at least one nonionic emulsifier is selected from the group consisting of esters of fatty alcohols, polyalkylenglycol alkyl ethers, polyalkyleneglycol fatty acid esters, glucoside alkyl ethers, alkyl glucose esters, glycerol alkyl esters, sorbitan fatty acid esters, block polymers of polyethylene glycol and block polymers of polypropylene glycol.
6. The topical composition according to claim 1, wherein the at least one nonionic emulsifier is selected from the group consisting of C.sub.12-C.sub.22-alkylester of C.sub.12-C.sub.22-alcohols, polyethylene glycol alkyl ethers, polyethylene glycol fatty acid esters, (polyglyceryl) alkylglucose alkyl esters, glycerol C.sub.12-C.sub.22 fatty acid esters and sorbitan mono fatty acid esters.
7. The topical composition according to claim 1, wherein the at least one nonionic emulsifier is selected from the group consisting of polyglycery 3 methylglucose distearate, cetearyl glucoside, methyl glucose sesquistearate, cetearyl olivate, sorbitan olivate, PEG-40 stearate, PEG-100 stearate, glyceryl stearate, steareth-2 and steareth-21.
8. The topical composition according to claim 1, wherein the co-emulsifier is selected from the group consisting of cetyl alcohol, behenyl alcohol, cetearyl alcohol and mixtures thereof.
9. The topical composition according to claim 1, wherein the co-emulsifier is present in an amount of 0.1 to 20 wt. %, based on the total weight of the composition.
10. The topical composition according to claim 1, wherein the composition comprises a preservative selected from the group consisting of phenoxyethanol, ethylhexylglycerin and mixtures thereof.
11. The topical composition according to claim 1, wherein the oily phase is present in an amount of less than 40 wt. % and the aqueous phase is present in an amount of at least 60 wt. %, based on total weight of the composition.
12. The topical composition according to claim 1, wherein the oily phase is present in an amount of less than 30 wt. % and the aqueous phase is present in an amount of at least 70 wt. %, based on total weight of the composition.
13. The topical composition according to claim 1, wherein the oily phase is present in an amount of 10-30 wt. % and the aqueous phase is present in an amount of 70-90 wt. %, based on total weight of the composition.
14. A method to retard or inhibit the re-crystallisation of 10-hydroxystearic acid or a salt thereof in an oil/water (O/W) topical composition comprising at least 10 wt. % of an oily phase and at least 50 wt. % of an aqueous phase, based on total weight of the composition, wherein the method comprises formulating 10-hydroxystearic acid or a salt thereof in the presence of at least one nonionic emulsifier and a co-emulsifier selected from the group consisting of nonionic solid fatty alcohols having from 12 to 22 carbon atoms and mixtures thereof in the absence of isobutylparabene.
15. The method according to claim 14, wherein the at least one nonionic emulsifier is selected from the group consisting of polyglycery 3 methylglucose distearate, cetearyl glucoside, cetearyl olivate, sorbitan olivate, methyl glucose sesquistearate, PEG-40 Stearate, PEG-100 stearate, glyceryl stearate, steareth-2 and steareth-21 and mixtures thereof.
16. The method according to claim 15, wherein the at least one nonionic emulsifier is selected from the group consisting of PEG-40 stearate, PEG-100 stearate, steareth-2 and steareth-21 and mixtures thereof.
17. The method according to claim 14, wherein the oily phase is present in an amount of less than 40 wt. % and the aqueous phase is present in an amount of at least 60 wt. %, based on total weight of the composition.
18. The method according to claim 14, wherein the oily phase is present in an amount of less than 30 wt. % and the aqueous phase is present in an amount of at least 70 wt. %, based on total weight of the composition.
19. The method according to claim 14, wherein the oily phase is present in an amount of 10-30 wt. % and the aqueous phase is present in an amount of 70-90 wt. %, based on total weight of the composition.
Description
EXAMPLE 1
(1) Various formulations using different emulsifiers (anionic (Ref) and nonionic (Inv)) have been prepared as outlined in Table 1 and 2. Initially, no crystals have been observed in any of the formulations by microscopy analysis. Then the formulations have been stored at room temperature and repeatedly been microscopically analyzed for re-crystallization of 10-hydroxystearic acid up to 3 months. The results thereof are outlined in Table 2.
(2) TABLE-US-00001 TABLE 1 INCI Wt.-% A Butyl Methoxydibenzoyl Methane 3.0 Octocrylene 2.7 Homosalate 5.0 Ethylhexyl Salicylate 5.0 C.sub.12-15 Alkyl Benzoate 5.0 Cetearyl Alcohol 2.0 Behenyl Alcohol 1.0 BHT 0.1 Acrylates/C.sub.10-30 Alkyl Acrylate Crosspolymer 0.1 10-Hydroxystearic Acid 1.0 Emulsifier See table 2 Stearic Acid B Xanthan Gum 0.2 Disodium EDTA 0.1 Butylene Glycol 2.0 Sodium Hydroxide 0.1 Aqua Ad 100 C Phenoxyethanol; Ethylhexylglycerin 1.0
Preparation Procedure
(3) 1st Heat part A to 90 C. and part B to 80 C.
(4) 2.sup.nd Combine part A and B and homogenize 1 minute at 10.000 rpm.
(5) 3.sup.rd Cool down while stirring.
(6) 4.sup.th Add part C at 35 C. while stirring.
(7) 5.sup.th At last, Cool down to RT while stirring.
(8) TABLE-US-00002 TABLE 2 microscopy aspect crystallization Emulsifier wt.-% after Ref Potassium Cetyl phosphate 2.0 2 weeks Ref Stearic Acid 8.0 2 weeks Ref C.sub.20-22 Alkyl Phosphate (And) C.sub.20-22 2.0 2 weeks Alcohols Ref Glyceryl Stearate Citrate 2.0 2 weeks Ref Disodium Cetearyl Sulfosuccinate 1.0 2 weeks Inv Polyglyceryl-3 Methylglucose 3.0 6 weeks Distearate Inv Cetearyl Olivate (and) Sorbitan Olivate 4.0 12 weeks Inv Cetearyl Glucoside 1.5 6 weeks Inv Methyl Glucose Sesquistearate 2.5 6 weeks Inv PEG-100 Stearate (and) Glyceryl 3.5 No crystals Stearate after 3 months Inv Steareth-2 (and) Steareth-21 2.5/1.0 No crystals after 3 months
(9) As can be retrieved from Table 2, the use of a nonionic emulsifier significantly retards or even inhibits the recrystallization of 10-hydroxystearic acid in a topical composition.
EXAMPLE 2
(10) A formulation comprising a nonionic, PEG-based emulsifier (PEG-40 Stearate) and an anionic emulsifier (stearic acid) as outlined in table 3 has been prepared.
(11) This formulation also did not result in any crystal formation, even after 3 months.
(12) TABLE-US-00003 TABLE 3 INCI Wt.-% BHT 0.1 10-Hydroxystearic Acid 1.0 Stearic Acid 17.0 Isopropyl Myristate 10.0 PEG-40 Stearate 5.0 Stearyl Alcohol 3.0 Sorbic Acid 0.2 Xanthan Gum 0.3 Aqua Ad 100 microscopy aspect No crystals after 3 months crystallization after: